The BEECH phase Ib/II trial (ClinicalTrials.gov identifier: NCT01625286) evaluated capivasertib, an AKT inhibitor, with paclitaxel vs. paclitaxel alone in HR+/HER2- BC. Here, ERBB2 is linked to breast cancer.